One Comprehensive Universal Radiotherapy for Everyone (1-CURE)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Contract Value
Not provided
Codes & Classification
Solicitation Number
ARPA-H-SOL-26-147
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AN13
Additional Details
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a solicitation for the One Comprehensive Universal Radiotherapy for Everyone (1-CURE) program. This initiative seeks innovative solutions to advance universal access to comprehensive radiotherapy, with the ultimate goal of improving health outcomes for diverse populations. The procurement is classified under NAICS code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and carries the product service code AN13.
ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements as a result of this solicitation, reflecting the agency’s commitment to fostering a broad range of research and development activities in biotechnology. The scope of the 1-CURE program is ambitious, aiming to catalyze the development and deployment of radiotherapy technologies and approaches that are universally accessible, effective, and scalable. Contractors are expected to propose comprehensive solutions that address technical, clinical, and operational challenges associated with radiotherapy, with an emphasis on inclusivity and resource sharing.
The solicitation has undergone several amendments to clarify proposal requirements and administrative procedures. Notably, Amendment 4 revises Appendix B to ensure consistency in proposal content, specifically designating Volume I, Element H as the Target Product Profiles (TPP) and renaming Volume I, Element I to Milestone Payment Schedule (MPS), with a prescribed format. The cost and pricing data support page limit has been removed, and a new cost proposal spreadsheet with resource sharing has been added as Appendix L. Previous amendments have introduced additional appendices and clarified administrative and national policy requirements, including the timing for submission of biographical and support forms.
Interested parties are encouraged to review the full solicitation and its appendices, which are available via the provided SAM.gov link. The agency has also issued a separate Special Notice (ARPA-H-SN-26-152) regarding the 1-CURE Proposers’ Day, offering further information and engagement opportunities for potential proposers. All questions related to the solicitation will be addressed and published on the 1-CURE Frequently Asked Questions (FAQ) page, which should be monitored regularly for updates.
The contracting entity is ARPA-H, a federal office within the NIH, and the primary point of contact for this opportunity is the 1-CURE Team, reachable at [email protected]. The solicitation remains active, with a response deadline of May 23, 2026. Contractors considering this opportunity should ensure their capabilities align with the research and development focus of the program, particularly in biotechnology and radiotherapy, and be prepared to meet the detailed proposal and administrative requirements outlined in the solicitation and its amendments.
For further information, including access to solicitation documents and FAQs, interested parties should consult the official SAM.gov opportunity page at https://sam.gov/opp/359c81244add413d86463d02643e5707/view.
Documents15